These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26130460)

  • 61. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pretreatment
    Gong C; Ma G; Hu X; Zhang Y; Wang Z; Zhang J; Zhao Y; Li Y; Xie Y; Yang Z; Wang B
    Oncologist; 2018 Oct; 23(10):1144-1152. PubMed ID: 30082489
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Breast Cancer Blood Flow and Metabolism on Dual-Acquisition
    Humbert O; Lasserre M; Bertaut A; Fumoleau P; Coutant C; Brunotte F; Cochet A
    J Nucl Med; 2018 Jul; 59(7):1035-1041. PubMed ID: 29439010
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
    Echavarria I; López-Tarruella S; Picornell A; García-Saenz JÁ; Jerez Y; Hoadley K; Gómez HL; Moreno F; Monte-Millan MD; Márquez-Rodas I; Alvarez E; Ramos-Medina R; Gayarre J; Massarrah T; Ocaña I; Cebollero M; Fuentes H; Barnadas A; Ballesteros AI; Bohn U; Perou CM; Martin M
    Clin Cancer Res; 2018 Apr; 24(8):1845-1852. PubMed ID: 29378733
    [No Abstract]   [Full Text] [Related]  

  • 65. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
    Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
    Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    BMC Cancer; 2011 Oct; 11():452. PubMed ID: 22011459
    [TBL] [Abstract][Full Text] [Related]  

  • 67. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
    Spring L; Greenup R; Niemierko A; Schapira L; Haddad S; Jimenez R; Coopey S; Taghian A; Hughes KS; Isakoff SJ; Ellisen LW; Smith BL; Specht M; Moy B; Bardia A
    J Natl Compr Canc Netw; 2017 Oct; 15(10):1216-1223. PubMed ID: 28982747
    [No Abstract]   [Full Text] [Related]  

  • 69. The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.
    Jebbink M; van Werkhoven E; Mandjes IA; Wesseling J; Lips EH; Vrancken Peeters MJ; Loo CE; Sonke GS; Linn SC; Falo Zamora C; Rodenhuis S
    Breast Cancer Res Treat; 2015 Aug; 153(1):145-52. PubMed ID: 26210520
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer.
    Bao J; Borja N; Rao M; Huth J; Leitch AM; Rivers A; Wooldridge R; Rao R
    Cancer Med; 2015 Apr; 4(4):500-6. PubMed ID: 25641925
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
    Martoni AA; Zamagni C; Quercia S; Rosati M; Cacciari N; Bernardi A; Musto A; Fanti S; Santini D; Taffurelli M
    Cancer; 2010 Feb; 116(4):805-13. PubMed ID: 20052718
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer.
    Woo JW; Han EK; Suh KJ; Kim SH; Kim JH; Park SY
    Breast Cancer Res Treat; 2024 Sep; 207(2):301-311. PubMed ID: 38753066
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
    Loibl S; Jackisch C; Lederer B; Untch M; Paepke S; Kümmel S; Schneeweiss A; Huober J; Hilfrich J; Hanusch C; Gerber B; Eidtmann H; Denkert C; Costa SD; Blohmer JU; Nekljudova V; Mehta K; von Minckwitz G
    Breast Cancer Res Treat; 2015 Jul; 152(2):377-87. PubMed ID: 26109347
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.
    Raccagni I; Belloli S; Valtorta S; Stefano A; Presotto L; Pascali C; Bogni A; Tortoreto M; Zaffaroni N; Daidone MG; Russo G; Bombardieri E; Moresco RM
    PLoS One; 2018; 13(5):e0197754. PubMed ID: 29791503
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Anticancer Res; 2023 Jan; 43(1):127-136. PubMed ID: 36585209
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.
    Groheux D; Hindié E; Giacchetti S; Delord M; Hamy AS; de Roquancourt A; Vercellino L; Berenger N; Marty M; Espié M
    J Nucl Med; 2012 Feb; 53(2):249-54. PubMed ID: 22241914
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.
    Kraus JA; Beriwal S; Dabbs DJ; Ahrendt GM; McGuire KP; Johnson RR; Badve P; Puhalla SL; Bhargava R
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):334-9. PubMed ID: 22417856
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and
    Nguyen-Thu H; Hanaoka H; Nakajima T; Yamaguchi A; Nguyen-Cong T; Kartamihardja AAP; Tsushima Y
    Breast Cancer; 2018 May; 25(3):334-342. PubMed ID: 29357023
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Shi Y; Lu H; Zhang Y
    Breast Cancer Res Treat; 2024 Jul; 206(2):387-395. PubMed ID: 38658447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.